PEPG

Healthcare Biotechnology

PepGen Inc.

$2.39

+0.09 +4.13% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 7, 2026, live at 3:46 PM ET	2.39

Key Stats

Market Cap

165.88M

Avg Volume

995,033

EPS

-$1.01

52W High

$7.80

52W Low

$1.31

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-2.31

P/B Ratio

1.39

EV/EBITDA

-0.79

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(75.5%)

Return on Assets

(39.1%)

Liquidity & Leverage

Current Ratio

13.36

Quick Ratio

13.02

Debt / Equity

0.13

Total Cash

117.24M

Total Debt

16.09M

About

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.